GGrantIndex
Sort

261,768 grants matching gene therapy

Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy

$2,283,892
Edmund A Rossi · Immunomedics, Inc. · R44 · FY2011 · CA

Molecular Center of Health and Disease

$2,283,750
Michael R Garrett · University Of Mississippi Med Ctr · P20 · FY2023 · GM

Weill Cornell Medicine (WCM) SPORE in Prostate Cancer

$2,283,108
Massimo F Loda · Weill Medical Coll Of Cornell Univ · P50 · FY2018 · CA

Disease mechanism and therapies for retinal degeneration

$2,283,094
Tiansen Li · National Eye Institute · ZIA · FY2019 · EY

Molecular Center of Health and Disease

$2,282,949
Michael R Garrett · University Of Mississippi Med Ctr · P20 · FY2024 · GM

Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment

$2,282,833
Scott Michael Schuetze · University Of Michigan At Ann Arbor · P50 · FY2022 · CA

p53, Aging, and Cancer

$2,282,517
Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Investigating and targeting apolipoprotein E4 in Down syndrome-associated Alzheimer's disease

$2,282,487
Noah Ray Johnson · University Of Colorado Denver · RF1 · FY2023 · AG

A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia

$2,282,414
David G. Nathan · Dana-Farber Cancer Inst · P50 · FY2012 · HL

Novel Mechanisms of Cardiac Injury and Repair

$2,281,940
Walter J Koch · Temple Univ Of The Commonwealth · P01 · FY2015 · HL

The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer

$2,281,895
Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA

KnowEng, a Scalable Knowledge Engine for Large-Scale Genomic Data-OVERALL

$2,281,452
Jiawei Han · University Of Illinois At Urbana-Champaign · U54 · FY2015 · GM

Architecture and control of exocytosis and endocytosis in excitable cells

$2,281,322
Justin Taraska · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL

Multimodal Developmental Neurogenetics of Females with ASD

$2,281,273
Kevin A. Pelphrey · University Of Virginia · R01 · FY2021 · MH

Ancillary Study

$2,281,109
Joshua A Boyce · Brigham And Women'S Hospital · U01 · FY2012 · HL

Full human gene-replacement mouse models of ADRDs

$2,280,898
Michael D Koob · University Of Minnesota · R33 · FY2021 · NS

Molecular Therapeutics for Anaplastic Gliomas

$2,280,865
University Of Alabama At Birmingham · P50 · FY2003 · CA

Mechanisms that Govern Cardiomyocyte Proliferation and Remuscularization following Ventricular Injury

$2,280,760
Jianyi Zhang · University Of Alabama At Birmingham · P01 · FY2024 · HL

SPORE: Targeted Therapies for Glioma

$2,280,112
Tracy T Batchelor · Massachusetts General Hospital · P50 · FY2017 · CA

Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center

$2,280,000
Richard G Wunderink · Northwestern University At Chicago · U19 · FY2022 · AI

Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center

$2,280,000
Richard G Wunderink · Northwestern University At Chicago · U19 · FY2021 · AI

MICRORNA AND NEURAL FACTOR-MEDIATED DIRECT REPROGRAMMING OF CELL FATES

$2,280,000
Andrew Yoo · Washington University · DP2 · FY2012 · NS

Section on Skeletal Disorders and Mineral Homeostasis

$2,279,342
Michael Collins · National Institute Of Dental & Craniofacial Research · ZIA · FY2017 · DE

Center for the Development of Phenotype-Based Treatments of Autism Spectrum Disorder

$2,279,021
David G Amaral · University Of California At Davis · P50 · FY2019 · HD

Genomic and epigenomic mechanisms of pediatric ocular disorders

$2,278,931
Robert Hufnagel · National Eye Institute · ZIA · FY2022 · EY